What Constitutes a Good Stock Dividend? An Insight into Three Healthcare Stocks

In the chaotic realm of the stock market, dividend stocks emerge as a beacon of stability. When share prices flounder or market trends waver, these stocks deliver consistent returns—a lifeline for those looking to either reinvest or manage day-to-day expenses.

Historically, tech stocks have been notorious for their lack of substantial dividends, as companies often redirect profits into business expansion or capital investments. In contrast, healthcare firms stand out as reliable dividend payers, despite also managing considerable research and development expenses. With an average dividend yield of 1.8% among healthcare stocks in the S&P 500, an investor seeking robust dividends should focus on options yielding over 2.5%. Below, three notable picks illustrate this trend.

AbbVie (NYSE: ABBV)

Headquartered in Illinois, AbbVie has carved a significant niche in the pharmaceutical industry, hailed for blockbuster drugs like Humira, which combats a range of conditions from arthritis to Crohn’s disease, alongside its oncology treatment, Imbruvica, and immunology products like Skyrizi and Rinvoq. With a staggering market capitalization of $385 billion and over $59 billion in revenue reported in the past year, AbbVie showcases impressive growth despite recent challenges.

In its recent fiscal quarter, AbbVie reported $15.8 billion in revenue, marking a 9.1% increase year-over-year, largely driven by Skyrizi, raking in $4.7 billion (up 46.8%) and Rinvoq contributing $2.2 billion (up 35.3%). However, this surge contrasts sharply with Humira’s decreasing sales, which fell to $993 million—down 55.4% due to lost exclusivity. AbbVie’s shares have appreciated by 20% this year, supplemented by a 3.1% dividend yield. The company is raising its dividend from $1.64 to $1.73 per share—an increase of 5.5%, effective February 17, 2026, for shareholders on record as of January 16, 2026.

UnitedHealth Group (NYSE: UNH)

Unlike AbbVie, UnitedHealth Group is having a tumultuous year, with its share price down 34% following dramatic declines earlier this year. Yet, this presents a prime opportunity for astute investors. As an integrated healthcare provider, UnitedHealth is in the midst of a crucial turnaround. Earlier setbacks stemmed from unmet expectations and a misjudgment of medical claims totaling $6.5 billion across its Medicare and employer plan portfolios.

Looking ahead, UnitedHealth is revising its Medicare Advantage offerings and collaborating with Medicare to enhance pricing structures for 2026-2027, which aims to secure better margins moving forward. Recent third-quarter results showcased promising recovery, boasting revenue of $113.2 billion—a 12% year-over-year increase. With a dividend yield of 2.6%, potential investors might consider UnitedHealth a worthwhile purchase as it inches toward recovery.

CVS Health (NYSE: CVS)

CVS Health has transformed dramatically since acquiring Aetna, broadening its operations into retail, insurance, and primary care. In the past quarter, CVS filled a staggering 461.4 million prescriptions and processed nearly half a billion pharmacy claims while serving 26.7 million members across its healthcare plans.

The company posted strong earnings with third-quarter revenues reaching $102.8 billion—a 7.8% increase from last year. Adjusted operating income surged to $3.45 billion, a 35% boost, while earnings per share rose from $1.09 to $1.60. CVS anticipates full-year revenues of at least $397 billion, alongside adjusted EPS guidance between $6.55 to $6.65. This remarkable growth catapulted CVS’s share price up by an astonishing 74% this year, while also delivering a solid 3.4% dividend yield.

Considering these dynamics, investors should weigh the potential of AbbVie, UnitedHealth Group, and CVS Health in their portfolios, keeping not only consistent returns but also the burgeoning prospects of these healthcare giants in mind.

The Motley Fool’s analyst team has pinpointed other promising stocks, excluding AbbVie from their top recommendations. Investors should remain vigilant in seizing opportunities that could yield substantial returns in the future.

Source: The Motley Fool

Source: finance.yahoo.com/news/considered-good-stock-dividend-3-160500226.html